{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-092626","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.364728+00:00","generated_at":"2026-05-31T07:46:54.770768+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Armata reports diSArm trial 80% enrolled, AP-PA02 topline data Sep 2024; Phase 3 planned for 2025","bullets":["diSArm Phase 1b/2a for AP-SA02 (S. aureus bacteremia) now 80% enrolled; completion expected Q4 2024.","AP-PA02 (P. aeruginosa bronchiectasis) enrollment completed; topline data expected September 2024.","Intravenous AP-SA02 and inhaled AP-PA02 well tolerated; early data show phage activity and persistence.","Phage candidates planned to enter pivotal Phase 3 trials in 2025, supported by $21.6M DoD grant.","Inhaled AP-PA02 monotherapy showed comparable to better bacterial load reduction vs antibiotics in blinded data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-092626","json":"https://secwatch.observer/filing/0001104659-24-092626.json","markdown":"https://secwatch.observer/filing/0001104659-24-092626.md","text":"https://secwatch.observer/filing/0001104659-24-092626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465924092626/0001104659-24-092626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465924092626/tm2422583d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:46:54.770768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}